Palantir Technologies lifts guidance after Q2 results beat Wall Street estimates
NEW YORK - Teva Pharmaceutical (TADAWUL:2070) Industries Ltd. (NYSE:TEVA) saw its shares climb 3.7% after the company reported first quarter earnings that beat analyst expectations and raised its full-year guidance.
The Israeli drugmaker posted adjusted earnings per share of $0.52 for Q1 2025, surpassing the consensus estimate of $0.48. Revenue came in at $3.9 billion, up 5% YoY in local currency terms, but slightly below analysts’ projections of $3.98 billion.
Teva’s key growth drivers showed strong momentum in the quarter. AUSTEDO revenues jumped 39% YoY to $411 million, while AJOVY sales increased 26% to $139 million. The company’s generics business also grew across all regions.
"Teva had a solid start to the year, with its ninth consecutive quarter of revenue growth," said CEO Richard Francis. He noted the company is "accelerating innovative growth and strengthening our generics business, while streamlining our operations."
Based on the Q1 performance, Teva raised its full-year 2025 earnings guidance to $2.45-$2.65 per share, up from its previous outlook of $2.35-$2.65. The company now expects 2025 revenue of $16.8-$17.2 billion, compared to its earlier forecast of $17.0-$17.4 billion.
The revised guidance reflects the divestiture of Teva’s Japan business venture, which closed on March 31. Excluding this impact, the company said its underlying full-year outlook increased.
Teva reaffirmed its target of achieving a 30% operating margin by 2027 as part of its "Pivot to Growth" strategy. The company announced plans for approximately $700 million in net cost savings by 2027 to help reach this goal.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.